
|Videos|November 3, 2022
Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape
Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.
Advertisement
Episodes in this series

Advertisement
Related to this article

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.

Thomas Powles, MBBS, MRCP, MD, discusses LITESPARK-022 QOL findings and patient selection for adjuvant belzutifan plus pembrolizumab in RCC.

Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
4
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
5

